ABSTRACT
To investigate potential interactions between stress, genetic predisposition, and breast cancer, we employed a multifaceted approach, analysing polygenic risk scores (PRS), DNA methylation (DNAm) patterns, stressful life events, and breast cancer risk using data from 10342 women in the Finnish Twin Cohort, including 719 breast cancer cases. Stressful life events data was gathered from a 1981 questionnaire while cancer and mortality data were obtained from Finnish Cancer Registry, Finnish Population Register and Statistics Finland. DNAm data from breast cancer discordant twin pairs was used to explore within-pair differences between 212 breast cancer associated CpG sites and stressful life events. A hazard ratio (HR) of 1.05 (95%CI 1.02-1.08) was observed for breast cancer per one-event increase in total stressful life events. Women exposed to over 10 stressful life events exhibited an almost two-fold increase in risk of breast cancer (HR=1.93, 95%CI 1.19-3.14). Stratifying by birth decade revealed a lower HR for those born after 1950 (HR 1.01; 95%CI 0.96-1.06) compared to those born between 1940-1949 (HR 1.07; 95%CI 1.01-1.12). In a subsample with genetic data, no association with breast cancer PRS was seen (HR = 1.03, 95%CI 0.92-1.15 per SD of PRS). Stressful life events exposure associated with breast cancer related DNAm in 42 of the 212 CpG sites. This 36-year genetically informed study highlights the long-term association between stressful life events and breast cancer risk. These findings suggest epigenetic changes, but not polygenic risk may mediate the impact the effects of stressful life events on breast cancer incidence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by funding from Biology of Trauma Initiative funding at the Broad Institute of MIT and Harvard (award 6910369-5500001940) to Jaakko Kaprio, Academy of Finland] (#328685, 307339, 297908 and 251316), Sigrid Juselius Foundation, Minerva Foundation and Medicinska Understodsforeningen Liv o Halsa r.f. to Miina Ollikainen, Cancer Foundation Finland (#67-6796) and Yrjo Jahnsson Foundation (#20237645) to Hannes Bode, and Emil Aaltonen Foundation to Mikaela Hukkanen (#23005).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the appropriate national research ethics committees, with the most recent approval granted by the Hospital District of Helsinki and Uusimaa ethics board in 2018 (#1799/2017). Permission for linkage to the Finnish Cancer Registry was provided by the Finnish Social and Health Data Permit Authority Findata (THL/6353/14.06.00/2023).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The genetic and epigenetic data and associated phenotypes utilized in the current study are stored in the Biobank of the Finnish Institute for Health and Welfare, Helsinki, Finland. The data is publicly available for use by qualified researchers through a standardized application procedure. https://thl.fi/en/web/thl-biobank/forresearchers. The epidemiological analysis data are available through the Institute for Molecular Medicine Finland (FIMM) Data Access Committee (DAC) (fimm-dac{at}helsinki.fi) for authorized researchers who have IRB/ethics approval and an institutionally approved study plan. To ensure the protection of privacy and compliance with national data protection legislation, a data use/transfer agreement is needed, the content and specific clauses of which will depend on the nature of the requested data. Requests will be addressed in a reasonable time frame and the primary mode of data access is by either personal visit or remote access to a secure server.
